These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 37195588)

  • 1. Measurable Residual Disease in Chronic Lymphocytic Leukemia: Current Understanding and Evolving Role in Clinical Practice.
    Rios-Olais FA; Hilal T
    Curr Treat Options Oncol; 2023 Aug; 24(8):907-928. PubMed ID: 37195588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal Residual Disease in Chronic Lymphocytic Leukemia in the Era of Novel Agents: A Review.
    Thompson M; Brander D; Nabhan C; Mato A
    JAMA Oncol; 2018 Mar; 4(3):394-400. PubMed ID: 28750119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
    García-Marco JA; Jiménez JL; Recasens V; Zarzoso MF; González-Barca E; De Marcos NS; Ramírez MJ; Parraga FJP; Yañez L; De La Serna Torroba J; Malo MDG; Ariznavarreta GD; Persona EP; Guinaldo MAR; De Paz Arias R; Llanos EB; Jarque I; Valle MDCF; Tatay AC; De Oteyza JP; Martin EMD; Fernández IP; Martinez RM; Costa MAA; Champ D; Suarez JG; Díaz MG; Ferrer S; Carbonell F; García-Vela JA;
    Haematologica; 2019 Nov; 104(11):2249-2257. PubMed ID: 30890600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL.
    Wierda WG; Kipps TJ; Al-Sawaf O; Chyla B; Biondo JML; Mun Y; Jiang Y; Seymour JF
    Leuk Lymphoma; 2022 Dec; 63(12):2765-2784. PubMed ID: 35983732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal residual disease in chronic lymphocytic leukaemia.
    García Vela JA; García Marco JA
    Med Clin (Barc); 2018 Feb; 150(4):144-149. PubMed ID: 28864095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of minimal residual disease in chronic lymphocytic leukemia.
    Al-Sawaf O; Hallek M; Fischer K
    Clin Adv Hematol Oncol; 2022 Feb; 20(2):97-103. PubMed ID: 35120090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evolving use of minimal residual disease (MRD) assessment in chronic lymphocytic leukemia.
    Cheson BD; Mato AR
    Clin Adv Hematol Oncol; 2020 Jun; 18 Suppl 10(6):1-20. PubMed ID: 33843867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance of Minimal Residual Disease in the Era of Targeted Therapies in Chronic Lymphocytic Leukemia.
    Al-Sawaf O
    Acta Haematol; 2024; 147(1):22-32. PubMed ID: 37903476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic Lymphocytic Leukemia: Time-Limited Therapy in the First-Line Setting and Role of Minimal Residual Disease.
    Stumpf J; Al-Sawaf O
    Curr Oncol Rep; 2024 Feb; 26(2):136-146. PubMed ID: 38175465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurable Residual Disease and Clinical Outcomes in Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis.
    Rios-Olais FA; McGary AK; Tsang M; Almader-Douglas D; Leis JF; Buras MR; Hilal T
    JAMA Oncol; 2024 Sep; 10(9):1221-1227. PubMed ID: 38990562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.
    Thompson PA; Wierda WG
    Blood; 2016 Jan; 127(3):279-86. PubMed ID: 26576865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relevance of Minimal Residual Disease in the Era of Targeted Agents.
    Heltai S; Ghia P; Scarfò L
    Cancer J; 2019; 25(6):410-417. PubMed ID: 31764122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.
    Kater AP; Seymour JF; Hillmen P; Eichhorst B; Langerak AW; Owen C; Verdugo M; Wu J; Punnoose EA; Jiang Y; Wang J; Boyer M; Humphrey K; Mobasher M; Kipps TJ
    J Clin Oncol; 2019 Feb; 37(4):269-277. PubMed ID: 30523712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MRD-directed therapy in CLL: ready for prime time?
    Rhodes JM; Lopez CA; Barrientos JC
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):413-420. PubMed ID: 38066928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
    Wierda WG; Allan JN; Siddiqi T; Kipps TJ; Opat S; Tedeschi A; Badoux XC; Kuss BJ; Jackson S; Moreno C; Jacobs R; Pagel JM; Flinn I; Pak Y; Zhou C; Szafer-Glusman E; Ninomoto J; Dean JP; James DF; Ghia P; Tam CS
    J Clin Oncol; 2021 Dec; 39(34):3853-3865. PubMed ID: 34618601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.
    Kovacs G; Robrecht S; Fink AM; Bahlo J; Cramer P; von Tresckow J; Maurer C; Langerbeins P; Fingerle-Rowson G; Ritgen M; Kneba M; Döhner H; Stilgenbauer S; Klapper W; Wendtner CM; Fischer K; Hallek M; Eichhorst B; Böttcher S
    J Clin Oncol; 2016 Nov; 34(31):3758-3765. PubMed ID: 27573660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?
    Al-Sawaf O; Seymour JF; Kater AP; Fischer K
    Hematol Oncol Clin North Am; 2021 Aug; 35(4):775-791. PubMed ID: 34102145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.
    Michallet AS; Letestu R; Le Garff-Tavernier M; Aanei C; Ticchioni M; Dilhuydy MS; Subtil F; Rouille V; Mahe B; Laribi K; Villemagne B; Salles G; Tournilhac O; Delmer A; Portois C; Pegourie B; Leblond V; Tomowiak C; De Guibert S; Orsini Piocelle F; Banos A; Carassou P; Cartron G; Fornecker LM; Ysebaert L; Dartigeas C; Truchan-Graczyk M; Vilque JP; Aurran T; Cymbalista F; Lepretre S; Levy V; Nguyen-Khac F; Feugier P
    Blood; 2021 Feb; 137(8):1019-1023. PubMed ID: 33167024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eradication of minimal residual disease in chronic lymphocytic leukemia.
    Schweighofer CD; Hallek M; Wendtner CM
    Curr Hematol Malig Rep; 2008 Jan; 3(1):54-60. PubMed ID: 20425447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.